Introduction
Cold-induced urticaria is a subtype of physical urticaria, which represents a rare disease with an incidence of 0.5% in Central Europe and higher incidence in regions with a colder climate. 1 Cold urticaria is triggered by exposure to local or environmental cold and manifests as localized or systemic pruritic papules, sometimes accompanied by angio-oedema and anaphylaxis representing a life-threatening condition. Lesions result from activation of skin mast cells, but the
Learning points
• Cold urticaria can manifest as oesophageal angio-oedema with oesophageal wall thickening and peri-oesophageal tissue oedema in atrial fibrillation patients undergoing cryoablation.
• Patients with cold urticaria should be carefully considered for an alternative energy source for pulmonary vein isolation or premedication with antihistamines when using cryoenergy. underlying pathomechanism of mast cell activation due to physical stimuli is incompletely understood. 2 Triggering factors include exposure to cold objects, cold liquids, and cold air. 3 Symptoms usually occur minutes after exposure but development of symptoms 24-48 h later is also described for delayed-type cold urticaria. 2 Wheals and angio-oedema are normally limited to areas exposed to cold triggers but extensive cold contact or contact to very low temperatures can induce a systemic reaction. Furthermore, contact of blood with hypothermia can be associated with systemic reactions like hypotension, laryngeal oedema, and cardiovascular failure. [4] [5] [6] Atrial fibrillation (AF) is the most common arrhythmia with a lifetime risk of 1:3. 7 Atrial fibrillation is a major cause of morbidity and mortality and is associated with increasing risks of death, heart failure, and stroke. 8 Besides medical treatment including control of heart rate and anticoagulation, definitive therapy includes catheter ablation with different energy sources, such as radiofrequency or cryoenergy, which has evolved to a curative treatment of AF in recent years. 9 Recently, it has been demonstrated, that cryoablation for pulmonary vein isolation (PVI) is at least as effective and potentially even superior to radiofrequency ablation in regards to safety and efficacy in the treatment of AF. 10, 11 We present the case of a 60-year-old man with therapy refractory AF and coincident cold urticaria who underwent cryoablation PVI.
GRAND ROUND

Timeline Case presentation
A 60-year-old man presented to our institution with paroxysmal AF that was highly symptomatic and refractory to antiarrhythmic medication. The patient had a history of cold-induced urticaria ( Figure 1 ) without occurrence of systemic reactions to date. The first onset of cold-induced urticaria occurred at the age of 40 years after contact with cold water and included localized wheals at the exposed areas. The wheals appeared minutes after exposure and resolved within hours. After first onset, the patient reported recurrent localized symptoms including wheals and angio-oedema at exposed areas after contact with cold water and cold air below 15 C. The patient reported no urticaria-associated hospitalization to date.
At physical examination, the patient presented in good physical condition. The blood pressure was 116/85 mmHg, basal oxygen saturation revealed 99%, and laboratory tests showed no pathologies. He reported no current gastrointestinal disorders or symptoms.
Oesophagogastroduodenoscopy (OGD) and endoscopic ultrasound (EUS) were performed directly prior and the day after PVI as part of the protocol for the MADE-PVI trial, 12 in which the patient was included. Pre-interventional OGD and EUS revealed no pathology of the oesophageal mucosa or the mediastinum. Pulmonary vein isolation was performed using Medtronic 2nd generation ArcticFront Cryoballoon guided by an Achieve mapping catheter. Pulmonary vein isolation was achieved in the left superior and inferior pulmonary veins employing a single freeze of 180 s per vein.
Temperature was decreased during balloon cooling to -43 C and -42 C, respectively. Subsequent PVI of the right inferior pulmonary vein (RIPV) and the right superior pulmonary vein (RSPV) was performed. Balloon cooling was stopped in the RSPV after 124 s and in the RIPV after 149 s of cooling time due to low temperature of -60 C and -64 C, respectively. Pacing manoeuvers confirmed complete electrical isolation of both right pulmonary veins. Post-interventional OGD, performed 18 h after PVI, revealed two longitudinal oedema with fissurated configuration in the middle oesophagus at 37-35 cm from the incisors (Figure 2A) . Additional EUS demonstrated that each oesophageal oedema included all layers of the oesophageal wall and was accompanied by small mediastinal oedema, which was strictly restricted to peri-oesophageal tissue ( Figure 2B) . Hereby, the localization of the oedema correlated with the anatomical altitude of the posterior wall of the left atrium. No oedema could be detected in the pericardial tissue surrounding the pulmonary vein ostia. The patient reported no gastrointestinal or systemic symptoms after PVI. Aetiologically, due to missing peri-atrial lesions, activation of cold urticaria during cryoablation rather than direct procedure-associated complications was suspected.
Oesophagogastroduodenoscopy and EUS 4 weeks later revealed a complete remission of all lesions without evidence of residual oedema in the oesophagus or mediastinum. During 6 weeks, 3 and 6 month of follow-up, the patient reported neither gastrointestinal symptoms nor recurrence of AF.
Discussion
Here, we report the first case of oesophageal manifestation of coldinduced urticaria by cryoballoon ablation of AF. Cold urticaria represents a rare but potentially life-threatening condition, which ranges from mild localized symptoms like wheals and angio-oedema to severe systemic anaphylactic reactions and is triggered by contact to cold stimuli. 4, 5 Even though symptoms are usually limited to localized lesions, systemic reactions may occur in a subset of patients. Two studies, including children and adults, reported that nearly 30% of patients with diagnosed cold urticaria had a history of severe systemic reactions, hypotension, or respiratory compromise. 1, 13 Even though aquatic activity was the strongest risk factor for systemic reaction, 30% of the patients with systemic symptoms just had contact with a cold object in these two studies. Risk factors for systemic reactions include history of previous systemic response or history of oropharyngeal oedema, age less than 30 years at disease onset, high amount To our knowledge and according to a review of the literature, this is the first report of cold urticaria after cryoablation. The lesions distinctly differed from classical PVI-associated oesophageal lesions, which typically reveal signs of local thermal injury like erosions, ulcerations, or necrosal lesions. 12 In this case, the detected lesions missed signs of thermal injury but revealed local angio-oedema of the oesophagus highly characteristic for physical urticaria-associated mucosal lesions. Besides, oesophageal wall thickening with reactive perioesophageal oedema, most probably due to the structural vicinity of the left atrium and the oesophagus was observed. Even though the (black arrows) with fissurated configuration in the middle oesophagus at 37-35 cm from the incisors (A). Additional endoscopic ultrasound demonstrated that each oesophageal oedema included all layers of the oesophageal wall and was accompanied by small mediastinal oedema, which was strictly restricted to peri-oesophageal tissue (B). patient was diagnosed before with cold urticaria, symptoms were limited to local reactions without any history of systemic symptoms like anaphylaxis or generalized skin reaction. Prophylactic medication was not given in this case due to the lack of history of systemic involvement. Nevertheless, our observation of oesophageal angio-oedema in this case stresses the risk of disease activation in patients with cold urticaria by using cryoenergy possibly leading to an increased risk for PVI-associated complications. Ablation of AF targets the pulmonary veins by placing lesions around their ostia to isolate AF triggers from the left atrium. Collateral damage to adjacent structures has been described, in particular to the mediastinum and the oesophagus, caused by its vicinity to the posterior wall of the left atrium. 14 Some studies, which have investigated mucosal changes of the oesophagus after AF ablation via oesophageal EUS, discovered structural changes of the mediastinum or the oesophagus in up to 27% of patients with radiofrequency energy. 11 In very rare cases (0. 05% 15 ), this may lead to formation of left atrial oesophageal fistulas with high mortality of up to 70%. 16 These data may lead to the hypothesis of a possibly increased risk for patients with cold urticaria-associated oesophageal angio-oedema and associated oesophageal wall thickening to develop severe complications like oesophago-atrial fistulas. Furthermore, very cold temperatures used during cryoablation and blood contact with cold stimuli both increase the risk for systemic symptoms. 4, 5 Thus, our observations of activated cold urticaria by cryoablation support the consideration of prophylactic medication in patients with severe cold urticaria undergoing cryoablation, even with the lack of history of systemic reactions. Primary preventive therapy comprises 2nd generation H1 antihistamines (e.g. cetirizine, loratadine, desloratadine, ebastine) as prophylactic therapy to reduce intensity or development of symptoms with less sedative side effects as compared to 1st generation antihistamines. 17 Lancey et al. 6 reported successful coronary bypass grafting including cold cardioplegia at 4 C in a patient with cold urticaria after receiving preoperative and postoperative prophylactic antihistamine therapy. Additionally, in patients with cold urticaria exposed to cold stimuli during surgery or interventions like cryoablation, the extent of symptoms and adequate prevention by antihistamines is not known and epinephrine should additionally be prepared as effective treatment for anaphylaxis. 18 Further pharmacologic therapies with possible prophylactic effects include leukotriene receptor antagonists and biologics in a small series of cases. Systemic glucocorticoids have been shown to induce divergent responses. Prednisolone in an oral dose of 20-25 mg for 1-5 days was tested in a small series of six cases with acquired cold urticaria following cold challenge and was proven to completely or partially reduce pruritus, but did not decrease the incidence of erythema or oedema. 19 Furthermore, Johnston et al. 20 described the case of a hypothermic cardiopulmonary bypass in a 47-year-old man with cold urticaria, in which prednisolone pre-treatment with 20 mg daily and preoperative hydrocortisone 100 mg could not prevent histamine release. In patients response to prednisolone therapy, improvement has been shown to be mostly only temporary. 21 Thus, routine or preventive treatment of cold urticaria with glucocorticoids is not generally recommended.
Taken together, we have demonstrated in this case report that cold urticaria can manifest as oesophageal angio-oedema with oesophageal wall thickening and peri-oesophageal tissue oedema in AF patients undergoing cryoablation. Since patients with cold urticaria may have a higher risk for developing systemic reaction, severe mediastino-oesophageal complications due to blood contact to very low temperatures and local angio-oedema in the vicinity of the cardio-circulatory system, these patients should be carefully considered for an alternative energy source for ablation or premedication with antihistamines when using cryoenergy.
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